Drug intelligence / Profile preview

RuVaCare(V)

Development stage: Preclinical
Lead developer: Theralase Technologies
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

RuVaCare(V) is an inactivated virus vaccine candidate developed by Theralase for the prevention of COVID-19. The vaccine is produced using a proprietary photodynamic inactivation technology. In this process, a photodynamic compound (PDC) is utilized to inactivate the SARS-CoV-2 virus, rendering it unable to replicate while preserving its structural integrity and essential antigenic properties. This inactivated virus is intended to elicit a protective immune response against SARS-CoV-2. The program is currently in the preclinical stage of development.

Brand names: RuVaCare(V)
Other names: RuVaCareV-TheralaseRuVaCare V-Theralase-SARS-CoV-2 virus-photodynamic compound (inactivated virus vaccine)-COVID-19

Beyond the preview

Go deeper on RuVaCare(V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RuVaCare(V).

Explore the full profile